| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EXACT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.10.2026 | 549 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 21.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.10.2026ISIN NameNO0010852213 EXACT... ► Artikel lesen | |
| 12.10. | XFRA 56F: AUSSETZUNG/SUSPENSION | 194 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXACT THERAP. AS... ► Artikel lesen | |
| 05.10. | EXACT Therapeutics: Further information for shareholders regarding the delisting | 1 | Oslo Børs | ||
| 04.09. | EXACT Therapeutics publishes shareholder information regarding the delisting | 1 | Oslo Børs | ||
| 31.08. | EXACT Therapeutics AS - Issuance of share options | 3 | Oslo Børs | ||
| 30.06. | EXACT Therapeutics AS - Removal from trading | - | Oslo Børs | ||
| 26.06. | EXACT Therapeutics AS: EXACT Therapeutics: Positive second safety read-out from the Phase 2 ENACT trial in pancreatic cancer | 1 | Oslo Børs | ||
| 17.06. | EXACT Therapeutics AS: Received application for delisting | - | Oslo Børs | ||
| 12.06. | EXACT Therapeutics AS: EXACT Therapeutics minutes from Annual General Meeting June 12, 2026 | 1 | Oslo Børs |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |